Lavanya Gurram
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lavanya Gurram has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
Umesh Mahantshetty
Homi Bhabha Cancer Hospital, Visakhapatnam, Tata Memorial Centre, Homi Bhabha National Institute, Parel, Mumbai, Maharashtra, India
7 shared publicationsSupriya Chopra
6 shared publications- Supriya Chopra
Department of Radiation Oncology, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institute, Kharghar, Navi Mumbai, Maharashtra, India
5 shared publications - Sudeep Gupta
Homi Bhabha National Institute, Mumbai, Maharashtra, India
4 shared publications - Umesh Mahantshetty
Department of Radiation Oncology, Homi Bhabha Cancer Hospital, Visakhapatnam, India
4 shared publications Yogesh Ghadi
4 shared publications
Latest Publications
- Open Access
- 23 June 2026
- Published by Elsevier in SSRN Electronic Journal
Transition From 2D to Image-Guided Adaptive Brachytherapy for Cervical cancer in India: Clinical Impact of AROI-ESTRO GYN Teaching Courses
Background and Purpose Six annual teaching courses were conducted in India between 2017 and 2023, focusing on image-guided adaptive brachytherapy (IGABT) for cervical cancer. The course curriculum was developed as a collaborative initiative between the Association of Radiation Oncologists of India (AROI) and the European Society for Radiation Oncology (ESTRO). The present study reports the academic and clinical impact of these courses. Material and Methods A detailed online master survey of all participants (456 participants from 184 institutions) was conducted in 2023 to understand the impact of these courses on knowledge and practice. The outcomes were compared with pre-course surveys. Results Participants from 104 institutions responded to the master survey while 101 who continued to practice cervical cancer brachytherapy at the time of the survey were included. As per baseline pre-course surveys, imaging used routinely for brachytherapy planning was X-rays (25%), CT (75%) and MRI (10%). IC+IS applications and IGABT were used by 31% and 35% participants, respectively. In the master survey, improvement in knowledge and practice of IGABT was reported by 94% and 87% of respondents, respectively. Meaningful improvements were reported in implementation of critical processes like use of clinical drawings (33%), ultrasound guidance (17%), IC+IS applications (25%), target-volume delineation (38%) and volume-based prescription (35%). Frequent reasons cited for inability to implement and sustain these critical processes included large patient volume, lack of infrastructure, suboptimal human resources etc. Conclusion The survey results suggest that such teaching courses improve implementation of IGABT workflows for cervical cancer in clinical practice. Conference Presentation The outcome was presented in the Oral Proffered presentation at World Congress in Brachytherapy in 10-13 July 2024 at Maryland USA.
- 23 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTransition From 2D to Image-Guided Adaptive Brachytherapy for Cervical cancer in India: Clinical Impact of AROI-ESTRO GYN Teaching Courses
Background and Purpose Six annual teaching courses were conducted in India between 2017 and 2023, focusing on image-guided adaptive brachytherapy (IGABT) for cervical cancer. The course curriculum was developed as a collaborative initiative between the Association of Radiation Oncologists of India (AROI) and the European Society for Radiation Oncology (ESTRO). The present study reports the academic and clinical impact of these courses. Material and Methods A detailed online master survey of all participants (456 participants from 184 institutions) was conducted in 2023 to understand the impact of these courses on knowledge and practice. The outcomes were compared with pre-course surveys. Results Participants from 104 institutions responded to the master survey while 101 who continued to practice cervical cancer brachytherapy at the time of the survey were included. As per baseline pre-course surveys, imaging used routinely for brachytherapy planning was X-rays (25%), CT (75%) and MRI (10%). IC+IS applications and IGABT were used by 31% and 35% participants, respectively. In the master survey, improvement in knowledge and practice of IGABT was reported by 94% and 87% of respondents, respectively. Meaningful improvements were reported in implementation of critical processes like use of clinical drawings (33%), ultrasound guidance (17%), IC+IS applications (25%), target-volume delineation (38%) and volume-based prescription (35%). Frequent reasons cited for inability to implement and sustain these critical processes included large patient volume, lack of infrastructure, suboptimal human resources etc. Conclusion The survey results suggest that such teaching courses improve implementation of IGABT workflows for cervical cancer in clinical practice. Conference Presentation The outcome was presented in the Oral Proffered presentation at World Congress in Brachytherapy in 10-13 July 2024 at Maryland USA.
- 18 April 2024
- Published by Elsevier in Brachytherapy
- Vol. 23 (4) , 407-415
Clinical outcomes of adaptive intracavitary and interstitial brachytherapy technique in locally advanced cervical cancer: A real-world data
- 18 April 2024
- Published by Elsevier in Brachytherapy
- Vol. 23 (4) , 407-415
Clinical outcomes of adaptive intracavitary and interstitial brachytherapy technique in locally advanced cervical cancer: A real-world data
- 31 October 2023
- Published by Cambridge University Press (CUP) in Journal of Radiotherapy in Practice
- Vol. 22, e113
Dosimetric comparison of sequential intensity-modulated radiation therapy (IMRT) and simultaneous integrated boost IMRT for lymph node-positive cervical cancer
Introduction: Nodal boost is being increasingly employed to escalate the dose to involved nodes in node-positive cervical cancer. The study aimed to compare the dosimetric differences between sequential boost intensity-modulated radiation therapy (SeB-IMRT) and simultaneous integrated boost IMRT (SIB-IMRT) in terms of target coverage and organs-at-risk (OARs) with special emphasis on the effect of nodal shrinkage and anatomical change of normal tissues during radiotherapy. Methods: Two computed tomography (CT) datasets (of phase I and phase II) of 40 patients of node-positive cervical cancer treated with SeB-IMRT [planning target volume (PTV) 45/25] followed by SeB to residual nodes (PTV 12·6/7) were utilised. SIB-IMRT1 plan consisted of PTV pelvis and para-aortic nodal region (PTV 45/25) and SIB to gross nodes (PTV 55/25). In order to account for the change in nodal and normal tissue topography during treatment, a third plan (SIB-IMRT2) was generated by utilising the SIB-IMRT1 plan for 44 Gy in 20 fractions and reproducing the plan on the second CT dataset for 11 Gy in 5 fractions. Dosimetric parameters of the three plans were compared using the Friedman test with Bonferroni correction. Results: We observed that the doses to OARs (bowel, rectum and bladder) were significantly higher in SeB-IMRT plan as compared to the SIB-IMRT plans. V40 Gy of bowel for SeB-IMRT, SIB-IMRT1 and SIB-IMRT2 plans were 354·8 cc, 271 cc and 321·8 cc, respectively (p = 0·001), whereas V30 Gy were 687·8 cc, 635·5 cc and 680 cc, respectively (p = 0·001). The target coverage was marginally better in SeB-IMRT plan as compared to SIB-IMRT1 and SIB-IMRT2 plans (V95% = 99·2 versus 97·7 versus 97·9, respectively, p = 0·000) Conclusion: SIB-IMRT led to better sparing of OARs, especially bowel. However, the magnitude of benefit decreases if the change in nodal and normal tissue topography during radiotherapy is not considered implying the need for frequent image guidance when SIB-IMRT is planned for node-positive cervical cancer.
- 31 October 2023
- Published by Cambridge University Press (CUP) in Journal of Radiotherapy in Practice
- Vol. 22, e113
Dosimetric comparison of sequential intensity-modulated radiation therapy (IMRT) and simultaneous integrated boost IMRT for lymph node-positive cervical cancer
Introduction: Nodal boost is being increasingly employed to escalate the dose to involved nodes in node-positive cervical cancer. The study aimed to compare the dosimetric differences between sequential boost intensity-modulated radiation therapy (SeB-IMRT) and simultaneous integrated boost IMRT (SIB-IMRT) in terms of target coverage and organs-at-risk (OARs) with special emphasis on the effect of nodal shrinkage and anatomical change of normal tissues during radiotherapy. Methods: Two computed tomography (CT) datasets (of phase I and phase II) of 40 patients of node-positive cervical cancer treated with SeB-IMRT [planning target volume (PTV) 45/25] followed by SeB to residual nodes (PTV 12·6/7) were utilised. SIB-IMRT1 plan consisted of PTV pelvis and para-aortic nodal region (PTV 45/25) and SIB to gross nodes (PTV 55/25). In order to account for the change in nodal and normal tissue topography during treatment, a third plan (SIB-IMRT2) was generated by utilising the SIB-IMRT1 plan for 44 Gy in 20 fractions and reproducing the plan on the second CT dataset for 11 Gy in 5 fractions. Dosimetric parameters of the three plans were compared using the Friedman test with Bonferroni correction. Results: We observed that the doses to OARs (bowel, rectum and bladder) were significantly higher in SeB-IMRT plan as compared to the SIB-IMRT plans. V40 Gy of bowel for SeB-IMRT, SIB-IMRT1 and SIB-IMRT2 plans were 354·8 cc, 271 cc and 321·8 cc, respectively (p = 0·001), whereas V30 Gy were 687·8 cc, 635·5 cc and 680 cc, respectively (p = 0·001). The target coverage was marginally better in SeB-IMRT plan as compared to SIB-IMRT1 and SIB-IMRT2 plans (V95% = 99·2 versus 97·7 versus 97·9, respectively, p = 0·000) Conclusion: SIB-IMRT led to better sparing of OARs, especially bowel. However, the magnitude of benefit decreases if the change in nodal and normal tissue topography during radiotherapy is not considered implying the need for frequent image guidance when SIB-IMRT is planned for node-positive cervical cancer.
- 15 September 2023
- Published by Elsevier in Brachytherapy
- Vol. 22 (6) , 753-760
Reirradiation with advanced brachytherapy techniques in recurrent GYN cancers
- 15 September 2023
- Published by Elsevier in Brachytherapy
- Vol. 22 (6) , 753-760
Reirradiation with advanced brachytherapy techniques in recurrent GYN cancers
- Open Access
- 24 March 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 8 (8)
Outcomes of Cervical Cancer in HIV-Positive Women Treated With Radiotherapy at a Tertiary Care Center in India
PURPOSE: There are limited data on management of cervical cancer in women living with HIV in the modern antiretroviral therapy era. The study aimed to evaluate outcomes and toxicities of these patients treated with radiotherapy. MATERIALS AND METHODS: A retrospective analysis of HIV-positive cervical cancer patients treated with radiotherapy between 2011 and 2018 was conducted at a tertiary care center in India. RESULTS: Eighty-two HIV-positive cervical cancer patients treated with radiotherapy were identified. Their median age was 45 years. Seventy-four (90%) patients received radiotherapy with curative-intent and eight patients received palliative radiotherapy. Median CD4 count at the start of treatment was 342 cells/mm3 (interquartile range: 241-531). Among patients planned for definitive radiotherapy, concurrent cisplatin was planned in 52 (70%) patients with a median of four chemotherapy cycles, and 81% (n = 60) patients received brachytherapy. Among patients who received brachytherapy, the median prescription dose was 80 Gy. Seventy-seven patients completed their prescribed treatment. At a median follow-up of 37 months, 3-year disease-free survival of patients planned with curative-intent was 54%. On multivariate analysis, treatment completion was associated with favorable disease-free survival. Grade III/IV acute gastrointestinal toxicity was seen in five (6.8%) patients, whereas 30% patients had grade III/IV acute hematologic toxicity. All these patients completed their planned radiotherapy with good supportive care. CONCLUSION: Standard treatment of chemoradiation should be planned in women living with HIV with well-managed HIV presenting with locally advanced cervical cancer. Our study highlights the need for optimal management of these patients by a multidisciplinary team with intensive supportive care to ensure completion of planned treatment to achieve better outcomes.
- 24 March 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 8 (8)
Open AccessOutcomes of Cervical Cancer in HIV-Positive Women Treated With Radiotherapy at a Tertiary Care Center in India
PURPOSE: There are limited data on management of cervical cancer in women living with HIV in the modern antiretroviral therapy era. The study aimed to evaluate outcomes and toxicities of these patients treated with radiotherapy. MATERIALS AND METHODS: A retrospective analysis of HIV-positive cervical cancer patients treated with radiotherapy between 2011 and 2018 was conducted at a tertiary care center in India. RESULTS: Eighty-two HIV-positive cervical cancer patients treated with radiotherapy were identified. Their median age was 45 years. Seventy-four (90%) patients received radiotherapy with curative-intent and eight patients received palliative radiotherapy. Median CD4 count at the start of treatment was 342 cells/mm3 (interquartile range: 241-531). Among patients planned for definitive radiotherapy, concurrent cisplatin was planned in 52 (70%) patients with a median of four chemotherapy cycles, and 81% (n = 60) patients received brachytherapy. Among patients who received brachytherapy, the median prescription dose was 80 Gy. Seventy-seven patients completed their prescribed treatment. At a median follow-up of 37 months, 3-year disease-free survival of patients planned with curative-intent was 54%. On multivariate analysis, treatment completion was associated with favorable disease-free survival. Grade III/IV acute gastrointestinal toxicity was seen in five (6.8%) patients, whereas 30% patients had grade III/IV acute hematologic toxicity. All these patients completed their planned radiotherapy with good supportive care. CONCLUSION: Standard treatment of chemoradiation should be planned in women living with HIV with well-managed HIV presenting with locally advanced cervical cancer. Our study highlights the need for optimal management of these patients by a multidisciplinary team with intensive supportive care to ensure completion of planned treatment to achieve better outcomes.
- 1 December 2021
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 165, 32-36
Validation and applicability of para-aortic lymph nodal contouring atlas in cervical cancer
- 1 December 2021
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 165, 32-36
Validation and applicability of para-aortic lymph nodal contouring atlas in cervical cancer
- Open Access
- 1 December 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 7 (7) , 843-848
Cervical Cancer Treatment in HIV-Positive Patients: A Survey of Treatment Practices in India
PURPOSE: Chemoradiation remains a challenge in women living with HIV (WLWH) and cervical cancer primarily because of concerns regarding immune status. With limited literature available to help guide the management of these patients, clinical practices among oncologists are variable across India. Hence, we conducted a survey among radiation oncologists in India to assess the patterns of current practices of treating cervical cancer with chemoradiation in WLWH. MATERIALS AND METHODS: A questionnaire consisting of 12 questions related to the treatment of cervical cancer in WLWH was distributed to radiation oncologists at two national conferences in India. RESULTS: The questionnaire was distributed to 105 radiation oncologists, and 90 (85.7%) responses were received. 95.5% of respondents reported that patients with advanced cervical cancer constituted the majority of their practice. Chemoradiation was reported as the most common modality of planned treatment. Ninety-four percentage of respondents reported that they referred patients to an antiretroviral therapy clinic before starting definitive treatment. The majority of respondents (68%) do not plan for concurrent chemotherapy if CD4 counts were < 200 cells/mm3. As many as 50% of respondents reported that they would only start antiretroviral therapy when CD4 counts drop. Poor social support (37.6%), concurrent infections during treatment (28.2%), acute toxicities (21.2%), and poor nutrition (13%) were cited as the most common reasons for treatment interruption in cervical cancer patients with HIV. CONCLUSION: This survey highlights the prevalent inconsistencies in treatment protocols employed by radiation oncologists in India for the management of locally advanced cervical cancer in WLWH. It also reflects the need for social and nutritional support to help improve compliance and thereby improve outcomes in these patients.
- 1 December 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 7 (7) , 843-848
Open AccessCervical Cancer Treatment in HIV-Positive Patients: A Survey of Treatment Practices in India
PURPOSE: Chemoradiation remains a challenge in women living with HIV (WLWH) and cervical cancer primarily because of concerns regarding immune status. With limited literature available to help guide the management of these patients, clinical practices among oncologists are variable across India. Hence, we conducted a survey among radiation oncologists in India to assess the patterns of current practices of treating cervical cancer with chemoradiation in WLWH. MATERIALS AND METHODS: A questionnaire consisting of 12 questions related to the treatment of cervical cancer in WLWH was distributed to radiation oncologists at two national conferences in India. RESULTS: The questionnaire was distributed to 105 radiation oncologists, and 90 (85.7%) responses were received. 95.5% of respondents reported that patients with advanced cervical cancer constituted the majority of their practice. Chemoradiation was reported as the most common modality of planned treatment. Ninety-four percentage of respondents reported that they referred patients to an antiretroviral therapy clinic before starting definitive treatment. The majority of respondents (68%) do not plan for concurrent chemotherapy if CD4 counts were < 200 cells/mm3. As many as 50% of respondents reported that they would only start antiretroviral therapy when CD4 counts drop. Poor social support (37.6%), concurrent infections during treatment (28.2%), acute toxicities (21.2%), and poor nutrition (13%) were cited as the most common reasons for treatment interruption in cervical cancer patients with HIV. CONCLUSION: This survey highlights the prevalent inconsistencies in treatment protocols employed by radiation oncologists in India for the management of locally advanced cervical cancer in WLWH. It also reflects the need for social and nutritional support to help improve compliance and thereby improve outcomes in these patients.
- 1 May 2021
- Published by Elsevier in Brachytherapy
- Vol. 20 (3) , 550-556
Reporting of dose–volume specifications for “Martinez Universal Perineal Interstitial Template–based interstitial high-dose-rate brachytherapy for gynecological cancers” according to International Commission on Radiation Units and Measurements 58 with early clinical outcomes
- 1 May 2021
- Published by Elsevier in Brachytherapy
- Vol. 20 (3) , 550-556
Reporting of dose–volume specifications for “Martinez Universal Perineal Interstitial Template–based interstitial high-dose-rate brachytherapy for gynecological cancers” according to International Commission on Radiation Units and Measurements 58 with early clinical outcomes
- 5 January 2021
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 19 (1) , 1-7
Treatment Compliance and Clinical Outcomes in Older Patients with Cervical Cancer Treated with Radio(chemo)therapy—A Retrospective Analysis
- 5 January 2021
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 19 (1) , 1-7
Treatment Compliance and Clinical Outcomes in Older Patients with Cervical Cancer Treated with Radio(chemo)therapy—A Retrospective Analysis
- Open Access
- 1 January 2021
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 13 (6) , 649-654
Modified Houdek vault applicator for high-dose-rate brachytherapy: a technical report and case series
Introduction Treatment of isolated post-surgical vault recurrence of cervical and endometrial cancers in previously unirradiated patients includes external beam radiotherapy (EBRT) ± concomitant chemotherapy, followed by brachytherapy (BT) boost. Supra-vaginal component of vault disease often...
- 1 January 2021
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 13 (6) , 649-654
Open AccessModified Houdek vault applicator for high-dose-rate brachytherapy: a technical report and case series
Introduction Treatment of isolated post-surgical vault recurrence of cervical and endometrial cancers in previously unirradiated patients includes external beam radiotherapy (EBRT) ± concomitant chemotherapy, followed by brachytherapy (BT) boost. Supra-vaginal component of vault disease often...